Global Fluvoxamine Maleate Tablets Market Growth 2025-2031

The global Fluvoxamine Maleate Tablets market size is predicted to grow from US$ 285 million in 2025 to US$ 357 million in 2031; it is expected to grow at a CAGR of 3.8% from 2025 to 2031.

Fluvoxamine maleate is an antidepressant medication belonging to the class of selective serotonin reuptake inhibitors (SSRIs). It is commonly prescribed to treat various mental health conditions, including major depressive disorder, obsessive-compulsive disorder (OCD), social anxiety disorder, and panic disorder. Fluvoxamine works by increasing the levels of serotonin, a neurotransmitter in the brain that plays a role in regulating mood and emotions.

The market for fluvoxamine maleate tablets is influenced by several factors:

Prevalence of Mental Health Disorders: The increasing prevalence of mental health disorders globally has contributed to the demand for medications like fluvoxamine maleate tablets. Improved awareness and diagnosis of these conditions have led to more patients seeking treatment and prescriptions for antidepressant drugs.

Rising Awareness and Reduced Stigma: Greater awareness and understanding of mental health issues have reduced the stigma associated with seeking treatment. This has encouraged more individuals to seek medical help for their mental health conditions, boosting the demand for antidepressant medications.

Growing Geriatric Population: The elderly population is more susceptible to mental health disorders, such as depression and anxiety. As the global population ages, the demand for antidepressants like fluvoxamine may increase to address the mental health needs of older adults.

Expanded Treatment Options: The availability of fluvoxamine as a generic medication may contribute to increased market penetration and affordability for patients seeking treatment for depression and anxiety disorders.

LP Information, Inc. (LPI) ' newest research report, the “Fluvoxamine Maleate Tablets Industry Forecast” looks at past sales and reviews total world Fluvoxamine Maleate Tablets sales in 2024, providing a comprehensive analysis by region and market sector of projected Fluvoxamine Maleate Tablets sales for 2025 through 2031. With Fluvoxamine Maleate Tablets sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Fluvoxamine Maleate Tablets industry.

This Insight Report provides a comprehensive analysis of the global Fluvoxamine Maleate Tablets landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Fluvoxamine Maleate Tablets portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Fluvoxamine Maleate Tablets market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Fluvoxamine Maleate Tablets and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Fluvoxamine Maleate Tablets.

This report presents a comprehensive overview, market shares, and growth opportunities of Fluvoxamine Maleate Tablets market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
25mg
50mg
75mg
100mg

Segmentation by Application:
Depression
Obsessive Compulsive Disorder(OCD)

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Upsher Smith Labs
Apotex
ANI Pharmaceuticals
Bionpharma
Actavis Elizabeth
Anchen Pharms
Jazz Pharmaceuticals
Abbott
Psycogen Captab
Meiji Seika Pharma
AbbVie
Kyorin Remedio
TAKATA Pharmaceutical
Nichi-Iko Pharmaceutical
Kyowa Pharmaceutical
Sawai Pharmaceutical
Nipro
Towa Pharmaceutical
Teva Takeda Yakuhin
Choseido Pharmaceutical
Hexal AG
Mylan
Stada Arzneimittel AG
Livzon

Key Questions Addressed in this Report

What is the 10-year outlook for the global Fluvoxamine Maleate Tablets market?

What factors are driving Fluvoxamine Maleate Tablets market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Fluvoxamine Maleate Tablets market opportunities vary by end market size?

How does Fluvoxamine Maleate Tablets break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.